Repligen Co. (NASDAQ:RGEN) Shares Sold by Pitcairn Co.

Pitcairn Co. cut its holdings in Repligen Co. (NASDAQ:RGEN) by 2.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,454 shares of the biotechnology company’s stock after selling 130 shares during the quarter. Pitcairn Co.’s holdings in Repligen were worth $641,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of RGEN. UMB Bank n.a. grew its holdings in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Repligen in the fourth quarter valued at $216,000. Worldquant Millennium Advisors LLC lifted its position in shares of Repligen by 11.9% in the third quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company’s stock valued at $7,482,000 after acquiring an additional 5,337 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Repligen by 7.8% during the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock valued at $6,078,000 after acquiring an additional 3,066 shares during the last quarter. Finally, Stephens Investment Management Group LLC increased its position in Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock worth $77,267,000 after purchasing an additional 37,057 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Down 8.0 %

RGEN opened at $111.94 on Friday. Repligen Co. has a 1 year low of $106.78 and a 1 year high of $182.52. The firm has a 50 day moving average price of $150.03 and a 200 day moving average price of $147.51. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market cap of $6.29 billion, a PE ratio of -219.49, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Sell-side analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have issued reports on RGEN. Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday. Royal Bank of Canada increased their price target on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Finally, TD Cowen began coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.